Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Cancer

Figure 1

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Figure 1

Increased expression of β-tubulin III and ERCC1 in ascites-derived tumor cells in response to paclitaxel. Expression and immunolocalisation of β-tubulin III and ERCC1 in ascites-derived tumor cells was evaluated by immunofluorescence using mouse monoclonal (green) and rabbit polyclonal (red) antibodies as described in the Methods. Cellular staining was visualized using secondary Alexa 488 (green) and Alexa 590 (red) fluorescent labelled antibodies while nuclear staining was visualized using DAPI (blue) staining. Images are representative of three independent experiments from three independent patient samples. The mean fluorescence intensity of β-tubulin III and ERCC1 was quantified using Cell-R software. Significant variations between the groups are indicated by *P < 0.05. Magnification 200×; scale bar = 10 μM.

Back to article page